Most telling though, the results that show that the overall obesity rate in the U.S. has not changed significantly in a ...

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filing in the gaps.

Americans who turned to telehealth companies and compounding pharmacies for cheap versions of Eli Lilly & Co.’s weight-loss ...

The FDA has resolved Eli Lilly's tirzepatide shortage, but localized supply issues persist. Meanwhile, Hims & Hers Health's ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 569.58% and ...

The FDA confirmed Thursday that Eli Lilly has increased production of its blockbuster weight-loss drug Zepbound and type 2 ...

Ozempic and similar drugs are often effective because they produce feelings of satisfaction, in line with the NBC theory of ...

Scaling GLP-1 manufacturing capacity remains a key priority for the pharma industry, to help supply catch up with the ...

The Food and Drug Administration declared an end to the scarcity of Eli Lilly's highly in-demand weight-loss and diabetes ...

BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, whose top-selling diabetes ...

The mayor of Rio de Janeiro is promising to make a generic version of Ozempic available through the city’s public health ...

The chip maker invested about $100 million in OpenAI's latest funding round, The Wall Street Journal reports. The CEO will need to convince investors that the company is still more than an auto maker.